Nevertheless, we should notice that attempts to identify pharmacological antagonists of CCR8 have been going on, and our work may implicate therapeutic targets of those small molecule inhibitors used on adjuvant therapy for non-metastatic ccRCC [19]. This evidence concerns the gene CCR8 and nonpapillary renal cell carcinoma.